29. September 2015
Document
New: Recombinant Gliadin Peptides
Pure gliadin peptides, recombinantly produced as easy-to-handle fusion with a carrier protein are now available.
In addition we provide antibodies to gliadin and cereal protein extracts like wheat gliadin for your research.
Find below the selection of our Recombinant Gliadin Peptides:
Albumin + globulin, prolamin and glutelin extracts from the cereals listed below are available: www.zedira.com/Cereal-Proteins.
In addition we provide antibodies to gliadin and cereal protein extracts like wheat gliadin for your research.
Find below the selection of our Recombinant Gliadin Peptides:
| Art. No. | Name | Unit | Price | |||||
| G051 | 26mer γ-gliadin peptide |  | 250 µg | 370 € | ||||
| G052 | 33mer α-gliadin peptide |  | 250 µg | 370 € | ||||
| G055 | Carrier protein control |  | 250 µg | 370 € | ||||
| G053 | 26mer DGP (DGPx1) |  | 250 µg | 370 € | ||||
| G054 | 33mer DGP |  | 250 µg | 370 € | ||||
| G006 | DGPx2 |  | 500 µg | 735 € | ||||
| G005 | DGPx4 |  | 500 µg | 735 € | ||||
| G056 | DGP and Gliadin peptides (Set No 1) (G051, G052, G053, G054 and G055, 100 µg each) | 1 Set | 740 € | |||||
Corresponding research tools: Antibodies to gliadin | ||||||||
| Art. No. | Name | Unit | Price | |||||
| A011 | Monoclonal antibody to gliadin (clone XGY1) (recognizes 26mer γ-gliadin peptide [G051], but not 33mer α-gliadin) | 1 mg | 365 € | |||||
| A064 | Monoclonal antibody to gliadin (clone XGY4) (recognizes 26mer γ-gliadin peptide [G051], and 33mer α-gliadin [G052] and corresponding DGP’s [G053, G054, G006, G005]) | 1 mg | 365 € | |||||
| A057 | Monoclonal antibody to deamidated Gliadin (specific to 33mer DGP [G054]) | 100 µg | 480 € | |||||
| Find further antibodies against gliadin and deamidated gliadin on our website www.zedira.com/Antibodies/Wheat-Gliadin. Cereal Proteins | ||||||||
| Art. No. | Name | Unit | Price | |||||
| G037 | Wheat prolamin (Gliadin) | 5 mg | 195 € | |||||
Document
Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira 
Discover Our New Catalogue Edition and Dive into the World of Transglutaminases! 
Successful ISO9001:2015 recertification 
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease 
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie 
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis 
Transcriptomic analysis of the efficacy of TG2-inhibitor trials and human intestinal organoids modelling Celiac disease pathogenesis 
Transglutaminase antibodies and neurological manifestations of gluten sensitivity 
Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible? 
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering 
Tridegin as FXIIIa inhibitor 
Microbial transglutaminase: from discovery to market 
Tissue transglutaminase inhibitors 
Tissue transglutaminase in Alzheimers Disease 
Factor XIIIa: novel target for anticoagulation? 
Microbial transglutaminase for site-specific protein conjugation